EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
- Citation:
- Br J Cancer vol 111 (6) 1065-1071
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Preliminary reports from this study were presented at the Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium 3–7 December 2012; San Antonio, TX (abstract 850544).
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 4
- Parents:
- 701
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821 , U10 CA180821, R01 CA-139431, CA-129949, R01 CA139431, P30 CA015083, R01 CA129949, U10 CA25224, U10 CA025224, U10 CA180888
- Corr. Author:
- Authors:
- H Cheng K Ballman M Vassilakopoulou A C Dueck M M Reinholz K Tenner J Gralow C Hudis N E Davidson G Fountzilas A E McCullough B Chen A Psyrri D L Rimm E A Perez
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- epidermal growth factor receptor, trastuzumab, tumour biomarker, immunofluorescence assay, breast cancer